Vitality Watch

Dossier pubmed preclinical 01-oct-2026
Animal model, organoid, or cell-culture result — not yet human

uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.

Key claim: A uPAR-targeting GFD-CD3 bispecific T-cell engager eliminates senescent cells and alleviates age-related pathologies in aged mice and non-human primates when low doses are guided by serum aminotransferase monitoring, offering a more dose-titratable alternative to senolytic CAR-T cells.

Abstract

Senolytic CAR-T cells targeting uPAR induce dose-dependent toxicities. Although dosage adjustment mitigates these toxicities in laboratory mice, clinical translation remains challenging owing to the unpredictability of CAR-T cell proliferation across heterogeneous patient populations. In contrast, bispecific T-cell engagers (BiTEs) offer a safer alternative with superior dose-titratability. Here, we have developed a GFD-CD3 BiTE by employing the growth factor-like domain (GFD) of the natural ligand uPA as the targeting moiety to target uPAR-positive senescent cells. Dose-range finding studies revealed that high-dose GFD-CD3 predominantly induced hepatotoxicity through T cell-mediated attack on hepatic endothelial cells. Crucially, under transaminase-guided monitoring, low-dose GFD-CD3 effectively eliminated senescent cells and alleviated age-related pathologies in aged mice and non-human primates without adverse effects. These findings establish GFD-CD3 as a clinically translatable senolytic agent and provide the compelling preclinical evidence for BiTE as a senolytic strategy.

Why this matters

Senolytic development has leaned on either small molecules (dasatinib+quercetin, fisetin) or living cell therapies (CAR-T), each with distinct problems — poor specificity on one end, undosable persistence on the other. A bispecific T-cell engager hitting the same uPAR antigen as senolytic CAR-T, but with a serum-aminotransferase safety dial and non-human primate data, is the first preclinical signal that T-cell-redirected senolysis might be delivered as a titratable drug rather than a one-shot cell product. The trend story to track is whether this reframes ‘senolytic immunotherapy’ away from CAR-T toward off-the-shelf biologics before any human aging data exist.

Source

Link

Briefing card

uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
Stage: preclinical · pubmed · 01-oct-2026

Applies to the preclinical pipeline for immuno-senolytics: uPAR-directed senescent-cell clearance now has a dose-titratable bispecific-antibody option tested in non-human primates, not just engineered T cells.

A uPAR-targeting GFD-CD3 bispecific T-cell engager eliminates senescent cells and alleviates age-related pathologies in aged mice and non-human primates when low doses are guided by serum aminotransferase monitoring, offering a more dose-titratable alternative to senolytic CAR-T cells.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/acel.70742

build build 880 · 2bcef25 · 2026-11-18